Class / Patent application number | Description | Number of patent applications / Date published |
514324000 | Ring sulfur in the polycyclo ring system | 38 |
20080207691 | Cycloalkyl Lactam Derivatives As Inhibitors Of 11-Beta-Hydroxysteroid Dehydrogenase 1 - The present invention provides compounds of formula I that are useful as potent and selective inhibitors of 11-beta hydroxysteroid dehydrogenase 1. The present invention further provides a pharmaceutical composition which comprises a compound of Formula I, or a pharmaceutical salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient. In addition, the present invention provides compositions comprising compounds of formula I for the treatment of metabolic syndrome, diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, other symptoms associated with hyperglycemia, and related disorders. Formula (I) wherein, Ru | 08-28-2008 |
20080207692 | Stabilized and preserved ketoifen ophthalmic compositions - Ophthalmic compositions comprising ketotifen and a source of hydrogen peroxide providing an amount of hydrogen peroxide of from about 0.001 to about 0.1% (w/v) of hydrogen peroxide, and methods for the treatment and prevention of allergic conjunctivitis using these compositions are provided herein. | 08-28-2008 |
20080287498 | Optically active isomers of ketotifen and therapeutically active metabolites thereof - Racemic norketotifen, racemic 10-hydroxy-ketotifen, racemic 10-hydroxy-nor-ketotifen and optically active isomers of ketotifen, norketotifen, 10-hydroxy-ketotifen and 10-hydroxy-norketotifen were found to have antiallergic and anti-inflammatory effects while being devoid of the severe dose-limiting sedative side effects of Ketotifen. | 11-20-2008 |
20080300277 | PROCESS TO IMPROVE STABILITY OF A PHARMACEUTICAL COMPOSITION - The present invention describes in particular a method for stabilizing a pharmaceutical composition by contacting said composition with a polymeric material comprising in particular an ethylene oxide sterilization step. | 12-04-2008 |
20090062344 | THERAPEUTIC SUBSTITUTED PIPERIDONE COMPOUNDS - Compounds comprising | 03-05-2009 |
20090069380 | DEUTERIUM-ENRICHED AROXIFENE - The present application describes deuterium-enriched arzoxifene, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-12-2009 |
20090069381 | DEUTERIUM-ENRICHED RALOXIFENE - The present application describes deuterium-enriched raloxifene, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-12-2009 |
20090137632 | Compositions And Methods For Treating Dyslipidemia - The present invention provides a method for treating dyslipidemia in a mammal, comprising administering to a mammal in need thereof, an effective amount of a compound of Formula (I): or a pharmaceutically acceptable salt or solvate thereof and at least one statin. | 05-28-2009 |
20090149502 | Optically active isomers of ketotifen and therapeutically active metabolites thereof - Racemic norketotifen, racemic 10-hydroxy-ketotifen, racemic 10-hydroxy-nor-ketotifen and optically active isomers of ketotifen, norketotifen, 10-hydroxy-ketotifen and 10-hydroxy-norketotifen were found to have antiallergic and anti-inflammatory effects while being devoid of the severe dose-limiting sedative side effects of Ketotifen. | 06-11-2009 |
20100105734 | Treatment xerophthalmia with norketotifen - Methods of using a cycloheptathiophene compound for the treatment of xerophthalmia are described, as are formulations and compositions for such treatment. | 04-29-2010 |
20100130550 | OCULAR FORMULATIONS OF NORKETOTIFEN - Ophthalmic compositions containing norketotifen and methods of making the same and the use thereof are disclosed. The methods also comprise administering to the eyes of a mammal in need thereof topical ophthalmic compositions containing norketotifen. | 05-27-2010 |
20100331365 | PIPERIDINE DERIVATIVE - The present invention provides a compound a piperidine derivative having excellent histamine receptor antagonistic action, which is useful as active ingredients of a pharmaceutical composition, especially an antihistamine. The piperidine derivative of the present invention has a potent histamine receptor antagonistic action. Further, the compound of the present invention shows low brain transfer even in a cerebral receptor binding test where a mouse is orally administered with the compound, so that the compound has preferred properties of alleviating side effects in the central nervous system, such as drowsiness. The piperidine derivative of the present invention is very useful as a novel antihistamine having smaller side effects in the central nervous system, such as drowsiness. | 12-30-2010 |
20110003854 | BREAST CANCER TREATMENT AND TREATMENT PREDICTION - The present invention provides a new method and means for determining whether a mammalian subject having a breast cancer is likely to benefit from an endocrine treatment. The method comprise the steps of: providing a sample earlier obtained from said subject; evaluating the amount of CRABP2 protein present in at least part of said sample, and determining a sample value corresponding to said amount; comparing the obtained sample value with a reference value; and, if said sample value is higher than said reference value, concluding that the subject is likely to benefit from an endocrine treatment. | 01-06-2011 |
20110009450 | Crystalline form of benzothiophene compound and process for preparation thereof - Crystalline raloxifene hydrochloride in hydrated form, particularly the monohydrate, processes for its preparation, pharmaceutical compositions comprising it and uses thereof. | 01-13-2011 |
20110028516 | STABILIZED AND PRESERVED KETOIFEN OPHTHALMIC COMPOSITIONS - Ophthalmic compositions comprising ketotifen and a source of hydrogen peroxide providing an amount of hydrogen peroxide of from about 0.001 to about 0.1% (w/v) of hydrogen peroxide, and methods for the treatment and prevention of allergic conjunctivitis using these compositions are provided herein. | 02-03-2011 |
20110065751 | Improved pharmaceutical composition containing a selective estrogen receptor modulator and method for the preparation thereof - The present invention relates to a pharmaceutical formulation of solid dosage forms comprising a therapeutically effective amount of a selective estrogen receptor modulator, and especially Raloxifene or a pharmaceutical acceptable salt thereof, in combination with a super disintegrant such as Primojel, and a process for the preparation thereof by wet granulation. | 03-17-2011 |
20110118313 | IDENTIFICATION OF A MOLECULAR SIGNATURE FOR ANTIPSYCHOTICS AND SERMS - Molecular signature for antipsychotics and SERMs has been identified, namely their upregulation of genes that alter lipid homeostasis, preferably of one or more of the following genes: TNSIG1, SCD, FADS2, LDLR, FDPS, ACAT2, FDFT1, CYP51A1, FASN, DHCR7, RAB26, TM7SF2, SATB1, FAM117, GPNMB, NUPR1, VAC14, and LSS. | 05-19-2011 |
20110160247 | Aralkyl alcohol piperidine derivative and the use thereof as a medicament for treating depression - The present invention relates to an aralkyl alcohol piperidine derivative and use as antidepressant thereo. The said aralkyl alcohol piperidine derivative has a triple inhibition effect on the reuptaking of 5-HT, NA and DA. The derivative may be administered to the patient in need of such treatment in the form of composition by oral administration, injection and the like. The derivative is a compound having the following general formula or its salt: | 06-30-2011 |
20110269796 | Use of Levocabastine for Modulating Generation of Pro-Inflammatory Cytokines - A composition for modulating generation of pro-inflammatory cytokines comprises levocabastine or a pharmaceutically acceptable salt or ester thereof. Such composition is useful for treating or controlling diseases having an inflammatory component, such as ocular diseases that are caused by inflammation or have inflammatory sequelae. | 11-03-2011 |
20110269797 | ANLN PROTEIN AS AN ENDOCRINE TREATMENT PREDICTIVE FACTOR - The present invention provides methods, uses and means for breast cancer prognostics and treatment prediction. Provided methods comprises the steps of: providing a sample earlier obtained from a breast cancer subject; evaluating the amount of ANLN protein present in at least part of said sample, and determining a sample value corresponding to said amount; comparing the sample value with a reference value; and, if said sample value is higher than said reference value, concluding that the subject is not likely to benefit from an endocrine treatment or that a prognosis for said subject is worse than a reference prognosis associated with the reference value. | 11-03-2011 |
20110312998 | Methods of Making and Using Stable Pharmaceutical Compositions Comprising Ketotifen and Naphazoline - Stable compositions comprising ketotifen or a ketotifen salt and methods of preparing such compositions are provided. The pH of the compositions remains at less than about 5 during storage. The methods comprise preparing pharmaceutical compositions comprising ketotifen or a ketotifen salt, and adjusting their pH to less than 5, thus slowing the changes of the active ingredients. | 12-22-2011 |
20120004265 | Ophthalmic Compositions and Methods of Using the Same - Ophthalmic compositions are provided that comprise or consist essentially of (a) ketotifen or a ketotifen salt, (b) a non-ionic tonicity agent, and (c) water. The concentration of ketotifen or the ketotifen salt is preferably from 0.01% to 0.05%. The non-ionic tonicity agent is preferably glycerol and the concentration of the glycerol is preferably from 4% to 7%. The compositions preferably have an osmolality of from 400 to 875 milliosmoles/Kg. The compositions may also contain an anti-redness agent. Methods of treating allergic conjunctivitis using the ophthalmic compositions and methods of treating dry eye disease using the ophthalmic compositions are also provided. | 01-05-2012 |
20120010245 | TRANSDERMAL PHARMACEUTICAL COMPOSITIONS COMPRISING A SERM - The present invention relates to transdermal pharmaceutical compositions such as gels containing a SERM selected from the group consisting of endoxifen, droloxifene, clomifene, raloxifene, tamoxifen, 4-OH tamoxifen, toremifene, danazol and the pharmaceutically acceptable salts thereof, and to methods of making and using the same. | 01-12-2012 |
20120095050 | STABILIZED AND PRESERVED KETOTIFEN OPHTHALMIC COMPOSITIONS - Ophthalmic compositions comprising ketotifen, a source of hydrogen peroxide providing an amount of hydrogen peroxide of from about 0.001 to about 0.1% (w/v), one or more ocular-compatible hydrogen peroxide stabilizers, HPMC and CMC, and methods for the treatment and prevention of allergic conjunctivitis using these ophthalmic compositions are provided herein. | 04-19-2012 |
20120122927 | 3 OR 4-SUBSTITUTED PIPERIDINE COMPOUNDS - There are disclosed racemic or enantiomerically enriched 3- or 4-substituted piperidine compounds represented by the following structural formula (I): | 05-17-2012 |
20120157496 | STABILIZED AND PRESERVED KETOTIFEN OPHTHALMIC COMPOSITIONS - Ophthalmic compositions comprising ketotifen and a source of hydrogen peroxide providing an amount of hydrogen peroxide of from about 0.001 to about 0.1% (w/v) of hydrogen peroxide, and methods for the treatment and prevention of allergic conjunctivitis using these compositions are provided herein. | 06-21-2012 |
20130102634 | Stabilized and Preserved Ketotifen Ophthalmic Compositions - Ophthalmic compositions comprising ketotifen, a source of hydrogen peroxide providing an amount of hydrogen peroxide of from about 0.001 to about 0.1% (w/v), one or more ocular-compatible hydrogen peroxide stabilizers, HPMC and CMC, and methods for the treatment and prevention of allergic conjunctivitis using these ophthalmic compositions are provided herein. | 04-25-2013 |
20130165480 | Stabilized and Preserved Ketotifen Ophthalmic Compositions - Ophthalmic compositions comprising ketotifen and a source of hydrogen peroxide providing an amount of hydrogen peroxide of from about 0.001 to about 0.1% (w/v) of hydrogen peroxide, and methods for the treatment and prevention of allergic conjunctivitis using these compositions are provided herein. | 06-27-2013 |
20130203812 | IONIC SILICONE HYDROGELS COMPRISING PHARMACEUTICAL AND/OR NUTRICEUTICAL COMPONENTS AND HAVING IMPROVED HYDROLYTIC STABILITY - The present invention relates to ionic silicone hydrogel polymers displaying improved thermal stability. More specifically, the present invention relates to a polymer formed from reactive components comprising at least one silicone component and at least one ionic component comprising at least one anionic group. The polymers of the present invention display good thermal stability and desirable protein uptake. | 08-08-2013 |
20130203813 | MEDICAL DEVICES HAVING HOMOGENEOUS CHARGE DENSITY AND METHODS FOR MAKING SAME - The present invention relates to ionic silicone hydrogel polymers comprising at least one pharmaceutical or nutriceutical component and displaying improved lysozyme uptake, low contact angle and reduced water soluble polymeric ammonium salt uptake. | 08-08-2013 |
20130345259 | Use of Levocabastine for Modulating Generation of Pro-Inflammatory Cytokines - A composition for modulating generation of pro-inflammatory cytokines comprises levocabastine or a pharmaceutically acceptable salt or ester thereof. Such composition is useful for treating or controlling diseases having an inflammatory component, such as ocular diseases that are caused by inflammation or have inflammatory sequelae. | 12-26-2013 |
20140011843 | METHODS FOR STABILIZING OXIDATIVELY UNSTABLE COMPOSITIONS - Ophthalmic compositions and methods of preparing such compositions are disclosed. | 01-09-2014 |
20140113936 | MEDICINAL TREATMENT OF DERMAL DISEASES IN COMPANION ANIMALS - The methods disclosed herein relate to the treatment of skin infections in dogs, by-administering a therapeutically effective amount of norketotifen. Therapeutic antimicrobial activity of norketotifen against | 04-24-2014 |
20140329859 | IONIC SILICONE HYDROGELS COMPRISING PHARMACEUTICAL AND/OR NEUTICEUTICAL COMPONENTS AND HAVING IMPROVED HYDROLYTIC STABILITY - The present invention relates to ionic silicone hydrogel polymers displaying improved thermal stability. More specifically, the present invention relates to a polymer formed from reactive components comprising at least one silicone component and at least one ionic component comprising at least one anionic group. The polymers of the present invention display good thermal stability and desirable protein uptake. | 11-06-2014 |
20150045392 | METHODS OF TREATING PRURITIC CONDITIONS MEDIATED THROUGH HISTAMINE H-4 RECEPTORS - The methods disclosed herein relate to the treatment of histamine H-4—related pruritus, by administering a histamine H-4 receptor inverse agonist that selectively accumulates at the biophases of the disorders, specifically RS-norketotifen or a pharmaceutically acceptable salt thereof. Potentiated antipruritic activity by simultaneous inhibition of histamine H-1 receptors and histamine H-4 receptors are described. | 02-12-2015 |
20150342944 | METHODS OF TREATMENT OF HISTAMINE H-4 RECEPTOR-RELATED PRURITUS ASSOCIATED WITH NERVE DISORDERS - The methods disclosed herein relate to the treatment of histamine H-4-related pruritus associated with nerve disorders, by administering a combined histamine H-1 and H-4 receptor inhibitor, specifically RS-norketotifen or a pharmaceutically acceptable salt thereof. Potentiated antipruritic activity by simultaneous inhibition of histamine H-1 receptors and histamine H-4 receptors are described. | 12-03-2015 |
20150376168 | SALT POLYMORPH OF THIOXANTHENE-9-YLIDENE-1-METHYL PIPERIDINE ACID ADDITION SALTS AS ANTIMIGRAINE COMPOUNDS - The present invention relates to novel crystal forms of 4-(6-ethoxy-1-methoxy-thioxanthene-9-ylidene)-1-methyl piperidine salts and 4-(6-ethoxy-1-hydroxy-thioxanthene-9-ylidene)-1-methyl piperidine salts; especially to novel crystal forms of 4-(6-ethoxy-1-methoxy-thioxanthene-9-ylidene)-1-methyl piperidine hydrochloride and 4-(6-ethoxy-1-hydroxy-thioxanthene-9-ylidene)-1-methyl piperidine hydrochloride as well as to the use of these salts for preventing or treating migraine or pulmonary hypertension. | 12-31-2015 |
20160193143 | MEDICINAL TREATMENT OF DERMAL INFECTIOUS DISORDERS WITH NORKETOTIFEN | 07-07-2016 |